Systemic lupus erythematosus and lupus nephritis

descriptionPublicationkeyboard_double_arrow_right Article 14 Feb 2014 English Publisher:Springer Science and Business Media LLCJournal:Nature Reviews Drug Discovery, volume 13, pages 173-174 (issn: 1474-1776, eissn: 1474-1784,

Copyright policy )

Authors: Toli, Koutsokeras; Tina, Healy;

doi: 10.1038/nrd4227

pmid: 24525782

Systemic lupus erythematosus and lupus nephritis

- Summary
- Subjects
- Metrics

Abstract

The late-stage pipeline for systemic lupus erythematosus (SLE) and lupus nephritis (LN) contains biologics and small-molecule drugs for a broad range of different targets. Koutsokeras and Healy discuss their likely impact on the future SLE and LN market.

Keywords

Biological Products, Clinical Trials as Topic, Anti-Inflammatory Agents, Non-Steroidal, Animals, Humans, Lupus Erythematosus, Systemic, Lupus Nephritis, Immunosuppressive Agents

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	65
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Top 10%
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Top 10%
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Top 10%